Shridhar J Pandya
Gplife Healthcare Pvt Ltd, India
Title: Impact of Gplife Advance Diabetic support tablet in Diabetes
Biography
Biography: Shridhar J Pandya
Abstract
Till date, Diabetic population is going to increase day by day, means something is missing with line of treatment. Diabetes mellitus (DM) is rising in India with more than 62 million diabetic individuals. India (31.7 million) topped world with highest number of people with DM followed by US. Prevalence of DM is predicted to double globally from 171 in 2000 to 366 million in 2030. Gplife Advanced Diabetic Support Tablet was suggestively effective in significantly effective in dropping levels of fasting plasma glucose (FPG) & post meal plasma glucose (PMG). It dropping levels of % HbA1C from baseline to day 60 i.e. end of study. It also significantly effective in increasing levels of C- peptide levels from baseline to day 60 i.e. end of study. C- Peptide is co-secreted with insulin form pancreas and could be used as a tool in diagnosis of DM. When compared to C peptide levels in overall patients there was improvement in c- peptide levels after treatment of Gplife Advanced Diabetic Support Tablet to DM patients. It increases in the HOMA-B score and there was significant decrease in the HOMA-IR score in DM patients. It was concluded that Gplife Advanced Diabetic Support Tablet” used as an adjuvant to OHA and insulin and helps in reducing fasting and post meal blood glucose level along with HbA1c. This can reduce the probable side effects of external insulin and OHA to subjects by providing result oriented and safer alternatives in management of DM